Published in PLoS One on October 07, 2009
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog (2010) 1.63
Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science (2014) 1.46
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS (2012) 1.29
Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection. J Virol (2012) 1.07
Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J Virol (2012) 1.06
A strong case for viral genetic factors in HIV virulence. Viruses (2011) 1.01
Transmission selects for HIV-1 strains of intermediate virulence: a modelling approach. PLoS Comput Biol (2011) 0.97
Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM? PLoS One (2013) 0.95
Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. PLoS Genet (2014) 0.91
Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology (2010) 0.91
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan. J Virol (2012) 0.88
How effectively can HIV phylogenies be used to measure heritability? Evol Med Public Health (2013) 0.85
HIV-1 dynamics: a reappraisal of host and viral factors, as well as methodological issues. Viruses (2012) 0.84
An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load. PLoS Comput Biol (2014) 0.84
The impact of antiretroviral therapy on population-level virulence evolution of HIV-1. J R Soc Interface (2015) 0.79
CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. AIDS (2015) 0.78
Associations of host genetic variants on CD4⁺ lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J (2014) 0.77
Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study. AIDS Res Ther (2015) 0.77
Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis. Evol Appl (2017) 0.76
Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013. Retrovirology (2013) 0.76
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A (2007) 3.29
Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis (2006) 3.03
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol (2000) 2.68
Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. Clin Infect Dis (2009) 2.50
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis (1999) 2.32
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS (2005) 1.99
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS (2006) 1.81
Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2000) 1.81
Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect (2001) 1.76
The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr (2007) 1.62
High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis (2009) 1.49
Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis (2007) 1.44
Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1997) 1.43
HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Res Hum Retroviruses (2004) 1.37
Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic. Sex Transm Infect (2008) 1.34
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr (2002) 1.30
Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles. J Clin Microbiol (1997) 1.14
Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens. J Clin Virol (2005) 1.13
Lack of evidence for changing virulence of HIV-1 in North America. PLoS One (2008) 1.11
Effectiveness of an opting-out strategy for HIV testing: evaluation of 4 years of standard HIV testing in a STI clinic. Sex Transm Infect (2008) 1.11
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10
Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA. J Virol Methods (1999) 1.09
Gender difference in HIV-1 RNA viral loads. HIV Med (2005) 1.08
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS (2009) 1.08
Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS (2005) 1.07
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
Temporal trends of the natural history of HIV-1 infection following seroconversion between 1984 and 1993. AIDS (1996) 1.05
No evidence of a change in HIV-1 virulence since 1996 in France. AIDS (2009) 1.05
Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA-QT. J Virol Methods (1997) 0.91
Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. The Human Immunodeficiency Virus Italian Seroconversion Study. Am J Epidemiol (1996) 0.90
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses (2000) 0.86
Flow cytometric lymphocyte subset enumeration: 10 years of external quality assessment in the Benelux countries. Cytometry B Clin Cytom (2008) 0.83
Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature (2005) 30.92
Strategies for mitigating an influenza pandemic. Nature (2006) 25.20
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science (2003) 12.26
Identification of a new human coronavirus. Nat Med (2004) 11.24
Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet (2003) 10.74
Rapid pneumococcal evolution in response to clinical interventions. Science (2011) 9.09
Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A (2008) 8.27
Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ (2009) 6.66
Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med (2009) 6.65
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med (2015) 6.25
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med (2006) 3.86
Public health. Public health risk from the avian H5N1 influenza epidemic. Science (2004) 3.71
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Fuzzy species among recombinogenic bacteria. BMC Biol (2005) 3.47
Host immunity and synchronized epidemics of syphilis across the United States. Nature (2005) 3.34
Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med (2011) 3.33
Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A (2007) 3.29
New strategies for the elimination of polio from India. Science (2006) 3.27
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18
Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med (2012) 3.14
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
West African Ebola epidemic after one year--slowing but not yet under control. N Engl J Med (2014) 2.96
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis (2007) 2.73
Seasonal infectious disease epidemiology. Proc Biol Sci (2006) 2.62
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. Arch Neurol (2009) 2.55
Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. Science (2009) 2.54
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci (2004) 2.45
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med (2004) 2.36
Assessing the reliability of eBURST using simulated populations with known ancestry. BMC Microbiol (2007) 2.36
Mathematical models of infectious disease transmission. Nat Rev Microbiol (2008) 2.32
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Whither or wither microbicides? Science (2008) 2.17
Ebola virus disease among children in West Africa. N Engl J Med (2015) 2.17
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
The impact of homologous recombination on the generation of diversity in bacteria. J Theor Biol (2005) 1.99
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology (2010) 1.98
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
A new framework and software to estimate time-varying reproduction numbers during epidemics. Am J Epidemiol (2013) 1.94
Sequences, sequence clusters and bacterial species. Philos Trans R Soc Lond B Biol Sci (2006) 1.91
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Identifying currents in the gene pool for bacterial populations using an integrative approach. PLoS Comput Biol (2009) 1.89
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr (2009) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet (2005) 1.84
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med (2010) 1.83
Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology (2015) 1.83
Retroviral superinfection resistance. Retrovirology (2005) 1.82
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis (2013) 1.73
Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics (2010) 1.72
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70